Oxford Immunotec Global PLC (NASDAQ:OXFD) has released a research-use-only assay, the T-SPOT Discovery SARS-CoV-2
test kit, that, it says, goes beyond simple serology like other
antibody tests by interrogating the immune system’s T cell response,
thereby measuring the strength of the response to coronavirus infection.
The T-SPOT technology is approved for clinical use
to detect TB in over 60 countries, including the U.S., China, Japan and
in Europe.
https://seekingalpha.com/news/3575828-oxford-releases-test-measures-immune-response-to-sars-covminus-2
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.